New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease
-- New data from a retrospective cohort study presented at major movement disorder congress
BRUSSELS, June 15 /PRNewswire-FirstCall/ -- New data from a
retrospective cohort study showed that up to three quarters of
patients with Parkinson's disease (PD) developed gastrointestinal
disorders (GID) that can have a substantial adverse effect on major
PD-related clinical and health economic outcomes. These data were
presented at the 14th International Congress of Parkinson's Disease
and Movement Disorders in Buenos Aires, Argentina (June 13-17,
2010).
"The new retrospective cohort study suggested that the
prevalence of gastrointestinal disorders among patients with
Parkinson's disease was high, increased over time and had a
significant impact on clinical and societal outcomes," said Dr.
Florent Richy, Head of Epidemiology, UCB & Adjunct Professor of
Epidemiology, University of Liege, Belgium. "Gastrointestinal
disorders can impair the onset of symptom relief by Parkinson's
disease drugs and these data help us to better understand the
prevalence and consequences of such disorders amongst patients
diagnosed with Parkinson's disease."
The study found that gastrointestinal disorders in PD patients
were associated with significantly higher rates of neuropsychiatric
and motor disorders, as well as increased emergency room
admissions, number of concurrent drugs and non-PD healthcare
costs.
About the Study
The new findings came from a two year matched retrospective
cohort study performed on a U.S. database of patient records
(Pharmetrics®)* which included demographic, diagnostic,
procedural and prescription information. Patients with at least two
prior diagnoses of Parkinson's disease and continuous prescriptions
of levodopa or dopamine agonists between 1st September 2005 and 1st
September 2006 were selected, and health outcomes and health
utilization patterns were followed up over a two year period.
Outcomes were defined on the basis of a literature review and
included neuropsychiatric, motor, urogenital disturbances,
healthcare utilization and related costs.
Four hundred and eighty five patients with Parkinson's disease
and GID were matched with 485 patients with Parkinson's disease and
without GID. In the data cut, GID incidence among patients with
Parkinson's disease and no history of GID increased over time,
stabilizing at 75% at 92 months. In addition GID was associated
with significantly higher rates of neuropsychiatric and motor
disorders, including psychosexual dysfunction (RR=8, p=0.05),
anxiety (RR=1.61, p<0.01), depression (RR=1.28, p=0.03), ataxia
(RR=1.24, p=0.03), pain (RR=1.29, p<0.01), movement disorders
(RR=1.39, p=0.02), urinary incontinence (RR=1.43, p=0.01) and risk
of fall (RR=1.44, p=0.03). Emergency room admissions (ratio=1.42,
p<0.01), number of concurrent drugs (ratio=1.06, p=0.04) and
Parkinson's disease and non-Parkinson's disease healthcare costs
(ratios=1.13 and 1.12, p<0.01 respectively) increased during the
observation period in the GID patients.
* This study was performed using a licensed IMS Pharmetrics®
datacut
Abstract: Gastrointestinal disorders in patients with
Parkinson's Disease: A double-edged sword
Richy F1, Gunn A2, Makaroff L3, Gervasoni C4, Helmers S5
1UCB Pharma SA, Brussels, Belgium & University of Liege,
Belgium; 2UCB Pharma SA, Brussels, Belgium; 3Business &
Development, Life Sciences, Brussels Belgium; 4Keyrus Biopharma,
Lasne, Belgium; 5Emory University School of Medicine, Atlanta,
US
Poster Session I, June 14th 2010, 0900-1800 For further information Eimear O Brien, Associate Director, Global CNS Communications T +32 2 559 9271, eimear.obrien@ucb.com Andrea Levin / Public Relations Manager, CNS, UCB, Inc. Office: 770.970.8352 / Mobile: 404.483.7329 / Email: andrea.levin@ucb.com About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical
company dedicated to the research, development and
commercialization of innovative medicines with a focus on the
fields of central nervous system and immunology disorders.
Employing more than 9 000 people in over 40 countries, UCB produced
revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext
Brussels (symbol: UCB).
Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual
results to be materially different from those that may be implied
by such forward-looking statements contained in this press release.
Important factors that could result in such differences include:
changes in general economic, business and competitive conditions,
effects of future judicial decisions, changes in regulation,
exchange rate fluctuations and hiring and retention of its
employees.
Source: UCB
CONTACT: Eimear O Brien, Associate Director, Global CNS
Communications,
+32-2-559-9271, eimear.obrien@ucb.com or Andrea
Levin, Public Relations
Manager, CNS, UCB, Inc., office, +1-770-970-8352 or mobile,
+1-404-483-7329,
andrea.levin@ucb.com
Web Site: http://www.ucb.com/
Posted: June 2010
